Join
Live feed
·
PRReleasevia Quantisnow
Arcus Biosciences Inc. logo

Initial Data from the ARC-20 Study of Casdatifan Plus Cabozantinib Showed Nearly Half of Patients with Metastatic Kidney Cancer Had a Confirmed Response

ByQuantisnow·Wall Street's wire, on your screen.
RCUS· Arcus Biosciences Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track RCUS (Arcus Biosciences Inc.) and more on Quantisnow.